奥扎格雷钠治疗早期脑梗死的疗效观察  

The Study of Ozagrel in the Treatment of Early Cerebral Infarction

作　　者：李明光[1] 杨恒连[2] 邓红琼[1] 李彦[1] 

机构地区：[1]山东省济南市第三人民医院神经内科,250101 [2]济南公安消防医院

出　　处：《中华全科医学》2010年第3期328-329,共2页Chinese Journal of General Practice

摘　　要：目的观察奥扎格雷钠治疗早期脑梗死的疗效。方法选择符合标准的脑梗死患者176例,随机分为奥扎格雷钠治疗组114例,对照组62例。治疗组静点奥扎格雷钠,80mg/次,2次/d;对照组静点维脑路通,0.4g/次,1次/d,均治疗2周。采用全国第四届脑血管病学术会议通过的"脑卒中患者临床神经功能缺损程度评分标准"进行疗效评定。结果奥扎格雷钠治疗组2周后临床神经功能缺损程度评定结果优于对照组。未发现明显副作用。结论奥扎格雷钠治疗急性脑梗死疗效明显,安全可靠。Objective To observe the clinical effect of Ozagrel in treatment of early cerebral infarction. Methods 176 eases of patients with cerebral infarction were randomly divided into treatment group （ Ozagrel, 114 patients） and control group（62 cases）. Infusion Ozagrel 80 mg/times ,2 times/d was adopted in treatment group. Control group： infusion Venoruton 0.4 g/times,1 times/d： Both were treated for weeks. Use of the Fourth national Cerebrovascular Disease Conference adopted a ＂standard score for stroke in patients with neurological impairment＂ for efficacy evaluation. Results The results of clinical assessment of neurological deficits of Ozagrel treatment group after two weeks had an advantage over the control group. No obvious side effects were found. Conclusion The treatment of acute cerebral infarction by Ozagrel was obvious,safe and reliable.

关 键 词：奥扎格雷钠 脑梗死 

分 类 号：R743.33[医药卫生—神经病学与精神病学] R972.7[医药卫生—临床医学]